Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE

por Mease, Philip J, Asahina, Akihiko, Gladman, Dafna D, Tanaka, Yoshiya, Tillett, William, Ink, Barbara, Assudani, Deepak, de la Loge, Christine, Coarse, Jason, Eells, Jason, Gossec, Laure
Publicado 2022

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study...

por Coates, Laura C., McInnes, Iain B., Merola, Joseph F., Warren, Richard B., Kavanaugh, Arthur, Gottlieb, Alice B., Gossec, Laure, Assudani, Deepak, Bajracharya, Rajan, Coarse, Jason, Ink, Barbara, Ritchlin, Christopher T.
Publicado 2022

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, acti...

por Ritchlin, Christopher T, Coates, Laura C, McInnes, Iain B, Mease, Philip J, Merola, Joseph F, Tanaka, Yoshiya, Asahina, Akihiko, Gossec, Laure, Gottlieb, Alice B, Warren, Richard B, Ink, Barbara, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, Landewé, Robert BM
Publicado 2023